SCHEMBL7208976

SCHEMBL7208976

CCNc1ccc(NC)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.50
ADRA2A P08913 7/20 0.48
ADRA2B P18089 3/20 0.48
ADRA2C P18825 3/20 0.48
LMNA P02545 1/20 0.48
TSHR P16473 1/20 0.46
APP P05067 4/20 0.41
ALDH1A1 P00352 2/20 0.39
RECQL P46063 2/20 0.39
HSD17B10 Q99714 2/20 0.39
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
TP53 P04637 1/20 0.39
CYP3A4 P08684 1/20 0.39
THRB P10828 1/20 0.39
HPGD P15428 1/20 0.39
ALOX15 P16050 1/20 0.39
CASP1 P29466 1/20 0.39
HIF1A Q16665 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10105579 0.93 ADRA2A (0.46) MAPTADRA2AADRA2BADRA2CLMNA
SCHEMBL526383 0.88 MAPT (0.58) MAPTADRA2AADRA2BADRA2CLMNA
SCHEMBL11616572 0.87 TSHR (0.67) MAPTADRA2AADRA2BADRA2CLMNA
Ammonia Solution, Strong SCHEMBL28483632 0.85 MAPT (0.56) MAPTADRA2AADRA2BADRA2CLMNA
Ammonia Solution, Strong SCHEMBL28486254 0.85 MAPT (0.56) MAPTADRA2AADRA2BADRA2CLMNA
Hydrochloric Acid SCHEMBL9181167 0.85 MAPT (0.56) MAPTADRA2AADRA2BADRA2CLMNA
SCHEMBL11699237 0.83 CA12 (0.52) MAPTLMNATSHRALDH1A1RECQL
SCHEMBL11747257 0.82 HCAR3 (0.49) MAPTLMNATSHRALDH1A1CA1
SCHEMBL1644806 0.81 HPGD (0.50) MAPTADRA2AADRA2BADRA2CLMNA
SCHEMBL28219541 0.81 MAPT (0.48) MAPTADRA2AADRA2BADRA2CLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023028524-A1 NEW ANTIDEGRADANTS BASED ON FATTY ACIDS OR DERIVATIVES FUNCTIONALIZED WITH PHENYLENEDIAMINES FLEXSYS AMERICA L.P. (US) 2023-03-02 WO disclosed
EP-3483149-B1 BENZO[D]THIAZOLE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME YUHAN CORP (KR) 2021-01-13 EP disclosed
US-10383859-B2 Benzo[d]thiazole derivative or salt thereof, and pharmaceutical composition including same YUHAN CORPORATION (KR) 2019-08-20 US disclosed
US-20190142809-A1 Benzo[D]Thiazole Derivative Or Salt Thereof, And Pharmaceutical Composition Including Same YUHAN CORPORATION (KR) 2019-05-16 US disclosed
EP-3483149-A1 BENZO[D]THIAZOLE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME Yuhan Corporation (KR) 2019-05-15 EP disclosed
EP-2877517-B1 PROCESS FOR FORMING AN ARAMID COPOLYMER DU PONT (US) 2017-01-04 EP disclosed
US-9155738-B2 Compounds for use in treatment of mucostitis CELLCEUTIX CORPORATION (US) 2015-10-13 US disclosed
US-20150094294-A1 COMPOUNDS AND METHODS FOR TREATING MALARIA NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2015-04-02 US disclosed
US-20140364364-A1 COMPOUNDS FOR USE IN TREATMENT OF MUCOSITIS INNOVATION PHARMACEUTICALS INC. 2014-12-11 US disclosed
US-8865875-B2 Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions MEDAREX, L.L.C. (US) 2014-10-21 US disclosed
US-8268970-B2 Human antibodies that bind mesothelin, and uses thereof BRISTOL-MYERS SQUIBB COMPANY (US) 2012-09-18 US disclosed
US-20110280891-A1 SITE-SPECIFIC ATTACHMENT OF DRUGS OR OTHER AGENTS TO ENGINEERED ANTIBODIES WITH C-TERMINAL EXTENSIONS E. R. SQUIBB & SONS, L.L.C. 2011-11-17 US disclosed
US-20110262448-A1 HUMAN ANTIBODIES THAT BIND MESOTHELIN, AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY (US) 2011-10-27 US disclosed
US-20100143368-A1 Human Antibodies That Bind Cd22 And Uses Thereof E. R. SQUIBB & SONS, L.L.C. 2010-06-10 US disclosed
US-20080279868-A1 Antibody-Drug Conjugates and Methods of Use MEDAREX, INC. (US) 2008-11-13 US disclosed
US-6613818-B1 Composition for back coating film of mirror formed on metallic protective film, comprising vehicle containing synthetic resin, salt formed by neutralization of acid with base containing metal having greater ionization tendency, and base CENTRAL GLASS COMPANY, LIMITED (JP) 2003-09-02 US disclosed
EP-0089101-A2 Direct positive image-forming process KONICA CORPORATION (JP) 1983-09-21 EP disclosed
US-4088587-A ANTIOXIDANT AND PHOSPHORUS-CONTAINING COMPOSITION CHEVRON RESEARCH COMPANY (US) 1978-05-09 US disclosed
US-4032462-A AN ANTIOXIDANT AND AN ORGANO-ANTIMONY COMPOUND CHEVRON RESEARCH COMPANY (US) 1977-06-28 US disclosed
US-3992307-A BIS-PHOSPHORAMIDE CHEVRON RESEARCH COMPANY (US) 1976-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140364364-A1 COMPOUNDS FOR USE IN TREATMENT OF MUCOSITIS MUC1, FUT6, MMP8 MAPT 4736/4885ADRA2A 4393/4885ADRA2B 4317/4885
US-20150094294-A1 COMPOUNDS AND METHODS FOR TREATING MALARIA PC, CPS1, GLS2 MAPT 1315/4885ADRA2A 3590/4885ADRA2B 4167/4885
US-20110280891-A1 SITE-SPECIFIC ATTACHMENT OF DRUGS OR OTHER AGENTS TO ENGINEERED ANTIBODIES WITH C-TERMINAL EXTENSIONS FCGR2A, FCGR3B, FCGRT MAPT 2327/4885ADRA2A 2551/4885ADRA2B 2820/4885
US-20110262448-A1 HUMAN ANTIBODIES THAT BIND MESOTHELIN, AND USES THEREOF EPCAM, CD44, MUC1 MAPT 3002/4885ADRA2A 4610/4885ADRA2B 4583/4885
US-20190142809-A1 Benzo[D]Thiazole Derivative Or Salt Thereof, And Pharmaceutical Composition Including Same ILK, SBDS, BDKRB1 MAPT 2062/4885ADRA2A 3691/4885ADRA2B 2723/4885
US-10383859-B2 Benzo[d]thiazole derivative or salt thereof, and pharmaceutical composition including same ILK, SBDS, BDKRB1 MAPT 2062/4885ADRA2A 3691/4885ADRA2B 2723/4885
US-20100143368-A1 Human Antibodies That Bind Cd22 And Uses Thereof CD2BP2, CD22, CD2 MAPT 3906/4885ADRA2A 2894/4885ADRA2B 3044/4885
US-20080279868-A1 Antibody-Drug Conjugates and Methods of Use CD47, ANTXR2, CD2BP2 MAPT 2234/4885ADRA2A 3856/4885ADRA2B 3775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.